J. Aries

Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients

J. Gribben, S. Montoto, J. Cavenagh, 2020, British journal of haematology.

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

J. Lambourne, John C. Riches, J. Aries, 2022, Leukemia research.

Managing HIV and Hodgkin Lymphoma in the Twenty-first century

S. Montoto, J. Aries, 2014, Current Hematologic Malignancy Reports.

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

J. Lambourne, John C. Riches, J. Aries, 2022, Leukemia research.

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients

S. Montoto, L. Drumright, S. Agrawal, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy

C. Várnai, R. Arnold, J. Cazier, 2021, British journal of haematology.

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

C. Craddock, M. Copland, S. Knapper, 2022, Blood.

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

N. Potter, C. Craddock, N. Russell, 2022, Blood.

Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD.

J. Gribben, J. Cavenagh, J. Lindsay, 2020, Blood.

Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience

J. Gribben, J. Cavenagh, M. Grantham, 2021, British journal of haematology.

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

N. Potter, C. Craddock, N. Russell, 2023, Leukemia.